临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 51322-75-9

Tizanidine

中文名称:替扎尼定
CAS号:51322-75-9
分子式: C9H8ClN5S 分子量: 253.71
产品形式: α2-adrenergic agonists
研发状态: Completed
研发用途: Malignant Melanoma Neoplasms
研究机构: Hoffmann-La Roche
研发日期: September 2 2013
研发阶段: Phase 1
Tizanidine is an imidazoline derivative and a centrally acting α2 adrenergic agonist used as a muscle relaxant for therapy of acute muscle spasms and chronic spasticity.

CAS: 51-30-9

Isoprenaline (NCI-C55630) HCl

中文名称:盐酸异丙肾上腺素
CAS号:51-30-9
分子式: C11H17NO3.HCl 分子量: 247.72
产品形式: Hydrochloride
研发状态: Completed
研发用途: Essential Hypertension
研究机构: University of Copenhagen; University of Aarhus
研发日期: August 1 2020
研发阶段: Not Applicable
Isoprenaline HCl (NCI-c55630,Isoproterenol hydrochloride) is a non-selective beta-adrenergic receptor agonist, used for the treatment of bradycardia and heart block.

CAS: 51-24-1

Tiratricol

中文名称:替拉曲可
CAS号:51-24-1
分子式: C14H9I3O4 分子量: 621.93
产品形式: free base
研发状态: Recruiting
研发用途: Monocarboxylate Transporter 8 Deficiency; Allan-Herndon-Dudley Syndrome
研究机构: Rare Thyroid Therapeutics International AB; Premier Research Group plc; Egetis Therapeutics
研发日期: July 21 2023
研发阶段: Phase 3
Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.

CAS: 51-21-8

Fluorouracil (5-Fluorouracil, 5-FU)

中文名称:5-氟尿嘧啶
CAS号:51-21-8
分子式: C4H3FN2O2 分子量: 130.08
产品形式: free base
研发状态: Recruiting
研发用途: Pancreatic Cancer; Adjuvant Therapy
研究机构: Kuirong Jiang; CSPC Ouyi Pharmaceutical Co. Ltd.; The First Affiliated Hospital with Nanjing Medical University
研发日期: April 8 2024
研发阶段: Not Applicable
Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.

CAS: 5119-48-2

Withaferin A

中文名称:醉茄素A
CAS号:5119-48-2
分子式: C28H38O6 分子量: 470.60
产品形式: free base
研发状态: Not yet recruiting
研发用途: Lynch Syndrome; Recurrent Uterine Corpus Carcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer
研究机构: Gynecologic Oncology Group; National Cancer Institute (NCI); GOG Foundation
研发日期: Jan-00
研发阶段: --
Withaferin A (WA, WFA) potently inhibits NF-κB activation by preventing the tumor necrosis factor-induced activation of IκB kinase β via a thioalkylation-sensitive redox mechanism. Withaferin A binds to the intermediate filament (IF) protein, vimentin with antitumor and antiangiogenesis activity. Withaferin A is a steroidal lactone isolated from Withania somnifera.

CAS: 51146-57-7

(R)-(-)-Ibuprofen

中文名称:(R)-布洛芬
CAS号:51146-57-7
分子式: C13H18O2 分子量: 206.28
产品形式: Free Base
研发状态: Recruiting
研发用途: Pain Postoperative
研究机构: B.P. Koirala Institute of Health Sciences
研发日期: August 10 2023
研发阶段: Phase 4
(R)-(-)-Ibuprofen ((R)-Ibuprofen) inhibits the activation of NF-κB in response to T-cell stimulation with IC50 of 121.8 μM, and exerts anti-inflammatory and antinociceptive effects.